DOCS Stock Price Today (April 2026) — Doximity, Inc. Analysis & Key Metrics 2026-04-02
Doximity, Inc. (DOCS) is trading at $21.46, down 6.41% today (as of April 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $39.55 (84.3% upside).
- Volatility remains elevated (20.23% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.80% YoY) alongside significant competitive pressures.
DOCS Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Doximity, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $3.48B
P/E Ratio
Forward P/E: 14.02
Revenue Growth
Year over Year
Analyst Target
+84.3% upside potential
Key Investor Questions About DOCS
What investors need to know before buying
Based on current market data, DOCS presents a oversold technical setup with looking solid fundamentals.
- Technicals say: Oversold (RSI 27.12)
- Fundamentals say: Looking solid (debt and growth supportive)
DOCS's growth trajectory depends on its ability to expand within the Health Information Services sector while managing margin pressures.
- Future growth will depend on performance in core Health Information Services operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for DOCS investors include debt exposure and competitive dynamics in the Health Information Services industry.
- $10.69M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Health Information Services.
52-Week Trading Range
Over the past year, DOCS stock traded between $21.82 and $76.51—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.23% annualized volatility and β=1.44, the stock exhibits high sensitivity to market moves—making DOCS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Doximity, Guidewire Software, Intuit, PagerDuty, and Health Catalyst Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after Anthropic announced Managed Agents, a hosted service for long-running AI tasks.
A Look Back at Vertical Software Stocks’ Q4 Earnings: Doximity (NYSE:DOCS) Vs The Rest Of The Pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Doximity (NYSE:DOCS) and the best and worst performers in the vertical software industry.
Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls
Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Coinbase Global, Diamondback Energy, Deere, Doximity, Dutch Bros., Johnson & Johnson, Robinhood Markets, Verizon and More
Pre-Market Stock Futures: The futures are exploding higher, as, fortunately, President Trump chose not to “end civilization in Iran” and agreed to a two-week pause on attacks on Iran. In contrast, Iran agreed to let ships pass through the Strait of Hormuz. The major indices were mixed after starting Tuesday deep in the red, then rallying in ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Coinbase Global, Diamondback Energy, Deere, Doximity, Dutch Bros., Johnson & Johnson, Robinh
How The Doximity (DOCS) Investment Story Is Shifting As Valuation And AI Expectations Reset
Doximity’s modeled fair value has been revised from about US$63.57 to roughly US$39.55, bringing it closer to the recent cluster of Street targets in the US$30 to US$60 range. That shift lines up with research that balances enthusiasm for the company’s healthcare network and AI tools, alongside more cautious views on execution risk and what counts as an appropriate valuation today. Read on to see how to track these evolving price targets and what they might mean for your own view on the...
Doximity’s SaaS Pivot And AI Tools Versus Its Recent Share Slump
Doximity (NYSE:DOCS) has shifted to a subscription first SaaS model, with about 95% of revenue now coming from recurring subscriptions. The company is increasing its focus on AI driven tools and telehealth features designed to help clinicians manage workflows and patient communication. These product changes are aimed at pharma and health system customers, as well as frontline clinicians using Doximity’s platform. For investors watching NYSE:DOCS, this business mix matters as much as the...
Doximity (DOCS) Outperforms Broader Market: What You Need to Know
The latest trading day saw Doximity (DOCS) settling at $23.06, representing a +1.27% change from its previous close.
Doximity: Clinician Network Leader
High-Margin SaaS with Narrow Moat in Healthcare IT
1 Profitable Stock to Target This Week and 2 We Turn Down
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?
Doximity's rising AI adoption and strong engagement contrast with Tempus AI's rapid growth but uncertain sustainability - so which stock stands out now?
Frequently Asked Questions
Common investor questions about Doximity, Inc.
Doximity, Inc. (DOCS) is currently trading at $21.46. The RSI (14-day) is at 27.1, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $39.55 implies 84.3% upside from current levels. Volatility is moderate at 20.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Doximity, Inc. (DOCS): The trailing P/E ratio is 19.13, which is in line with broader market averages. The forward P/E is 14.02, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.63, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 4.30. Price-to-Sales is 6.72. Valuation should be compared to Health Information Services industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering DOCS, the consensus price target is $39.55. This represents a 84.3% upside from the current price of $21.46. The range spans from a low target of $25.00 to a high target of $56.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Doximity, Inc. (DOCS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Doximity, Inc. (DOCS) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Health Information Services sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Doximity, Inc.'s (DOCS) current debt and financial health profile: Total debt stands at $10.69M. The debt-to-equity ratio is 1.09, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.63, indicating strong short-term liquidity. The quick ratio is 6.00. The company holds $735.13M in cash and equivalents. Free cash flow is positive at $213.63M, providing a cushion for debt servicing and shareholder returns.